Posted by Michael Wonder on 28 Feb 2023
CStone announces China’s NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastro-oesophageal junction adenocarcinoma
28 February 2023 - This supplementary new drug application was filed for the fourth indication for sugemalimab in China, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma.
CStone Pharmaceuticals announced today that the NMPA of China has accepted the supplementary new drug application for sugemalimab in combination with chemotherapy as a first-line treatment of unresectable locally advanced or metastatic gastric/gastro-oesophageal junction adenocarcinoma.
